Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.

Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM.

Mol Cell Biol. 2010 Mar;30(5):1243-53. doi: 10.1128/MCB.01891-08. Epub 2010 Jan 4.

2.

Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.

Reebye V, Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, Walker MM, Whitaker HC, Wait R, Hurst HC, Bevan CL.

Mol Endocrinol. 2012 Oct;26(10):1694-706. Epub 2012 Aug 16.

3.

The co-chaperone p23 promotes prostate cancer motility and metastasis.

Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, Abroaf A, Gaughan L, Robson CN, Heer R, Mauri F, de Rooij J, Driouch K, Bevan CL.

Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6.

4.

FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.

Periyasamy S, Hinds T Jr, Shemshedini L, Shou W, Sanchez ER.

Oncogene. 2010 Mar 18;29(11):1691-701. doi: 10.1038/onc.2009.458. Epub 2009 Dec 21.

5.

Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer.

Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR.

J Urol. 2005 May;173(5):1772-7.

PMID:
15821585
6.

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.

De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, Chen Y, Ning YM, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11878-83. doi: 10.1073/pnas.1105160108. Epub 2011 Jul 5.

7.

Effect of geldanamycin on androgen receptor function and stability.

Vanaja DK, Mitchell SH, Toft DO, Young CY.

Cell Stress Chaperones. 2002 Jan;7(1):55-64.

9.

Essential role for Co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology.

Yong W, Yang Z, Periyasamy S, Chen H, Yucel S, Li W, Lin LY, Wolf IM, Cohn MJ, Baskin LS, Sánchez ER, Shou W.

J Biol Chem. 2007 Feb 16;282(7):5026-36. Epub 2006 Dec 1.

10.

The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.

Leach DA, Trotta AP, Need EF, Risbridger GP, Taylor RA, Buchanan G.

Prostate. 2017 Feb;77(2):185-195. doi: 10.1002/pros.23259. Epub 2016 Oct 8.

PMID:
27718274
11.

The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.

Periyasamy S, Warrier M, Tillekeratne MP, Shou W, Sanchez ER.

Endocrinology. 2007 Oct;148(10):4716-26. Epub 2007 Jul 5.

12.
13.

Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.

Makkonen H, Kauhanen M, Paakinaho V, Jääskeläinen T, Palvimo JJ.

Nucleic Acids Res. 2009 Jul;37(12):4135-48. doi: 10.1093/nar/gkp352. Epub 2009 May 11.

14.

Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.

Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, Butler LM, Marshall VR, Scher HI, Gerald WL, Coetzee GA, Tilley WD.

Cancer Res. 2007 Oct 15;67(20):10087-96.

15.

Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.

Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL.

Mol Endocrinol. 2008 Mar;22(3):597-608. Epub 2007 Dec 13.

16.

Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.

Ito S, Ueda T, Ueno A, Nakagawa H, Taniguchi H, Hongo F, Kamoi K, Okihara K, Kawauchi A, Miki T.

FEBS J. 2014 Oct;281(19):4506-18. doi: 10.1111/febs.12959. Epub 2014 Aug 26.

17.

Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.

Terry S, Yang X, Chen MW, Vacherot F, Buttyan R.

J Cell Biochem. 2006 Oct 1;99(2):402-10. Review.

PMID:
16741972
18.

Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.

Kaikkonen S, Paakinaho V, Sutinen P, Levonen AL, Palvimo JJ.

Mol Endocrinol. 2013 Feb;27(2):212-23. doi: 10.1210/me.2012-1313. Epub 2012 Nov 28.

19.

Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease.

Guy NC, Garcia YA, Cox MB.

Curr Mol Pharmacol. 2015;9(2):109-25. Review.

PMID:
25986565
20.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

Supplemental Content

Support Center